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The term oligometastatic disease (OMD) has been coined 
in 1995 (1) for patients with a limited number of metastases 
that may be treated with a potentially curative intention. 
This intermediate cancer state between localized and 
metastatic disease was considered rare and both clinical 
and pre-clinical research was limited. In the recent years, 
however, OMD gained relevance in particular due to 
prospective studies highlighting the therapeutic relevance 
of targeting oligometastatic lesions with locally ablative 
procedures, such as surgery or stereotactic radiotherapy. 
Aside from prostate and colorectal cancer (2,3), non-
small cell lung cancer (NSCLC) has emerged as one of 
the major entities of interest. Among the most influential 
publications on oligometastatic NSCLC is the study by 
Gomez et al. comparing local consolidative therapy (LCT) 
and maintenance therapy or observation to maintenance 
therapy or observation which was first published in 2016 (4). 
At that time, the authors reported a significantly improved 
progression-free survival (PFS) and a delay of metastatic 
progression. In May 2019, the authors provided an update 
with overall survival (OS) data and additional secondary 
endpoints (5). 
In this randomized, multi-institutional phase II trial, 
patients with stage IV NSCLC and three or fewer 
metastases who did not show progression after completing 
three months of systemic therapy were randomized to 
either LCT and maintenance systemic therapy/observation 
or maintenance systemic therapy/observation (MT/O) 
alone. As recruitment started in 2012, options for systemic 
therapy included platinum doublet chemotherapy, 
epidermal growth factor receptor (EGFR)-inhibitors such 
as erlotinib as well as crizotinib for patients with activating 
driver mutations. EGFR mutations were present in three 
patients in each arm (12% respectively) and two patients in 
the LCT arm (8%) had anaplastic lymphoma kinase (ALK) 
rearrangement. Immunotherapy was not a component 
of this study. Due to a very high (99.46%) probability of 
superiority of the LCT arm in a planned interim analysis 
of the Data Safety Monitoring Board, the trial was closed 
early. Median PFS was 14.2 months for patients in the LCT 
arm compared to 4.4 months in the MT/O arm (log-rank 
P=0.022). This difference in PFS translated into a difference 
in OS with a median OS of 42.2 months for patients in 
the LCT arm compared to 17.0 months in the MT/O arm 
(P=0.017). While no grade 4 adverse events were observed, 
grade 3 events occurred in 5 out of 25 patients in the LCT 
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arm (two cases of radiation-induced esophagitis, one case 
of anemia after radiotherapy to the spleen likely related to 
treatment, one rib fracture possibly related to treatment, 
one case of abdominal pain unrelated to treatment) and two 
out of 24 patients in the MT/O arm (one case of fatigue, 
one case of anemia).
Limitations in the definition of OMD
An overview of relevant studies on oligometastasis in 
NSCLC can be found in Table 1. Even though OMD is 
becoming more and more recognized in daily clinical 
practice, a clear definition of what exactly constitutes 
this cancer state is still lacking. Definitions of OMD are 
currently imaging-based as biomarkers that differentiate 
between truly oligometastatic patients and patients 
with diffuse micrometastatic disease are not clinically 
established. This imaging-based definition gives rise to 
problems such as the difficulty to compare the results of 
studies using different imaging modalities or how to deal 
with increasingly more sensitive novel imaging modalities 
for patient staging. This shows the need for consensus 
guidelines of imaging-based diagnosis of OMD as it has 
been done for example in prostate cancer where standard as 
well as modern methods such as prostate-specific membrane 
antigen− (PSMA−) PET are available (8).
While the number of metastases has been defined as a 
criterion in all studies on oligometastatic cancer, the exact 
number differs and the three or fewer metastases in the 
Gomez et al.’s study are on the lower end of the spectrum. 
However, one needs to carefully consider the difference 
between the maximum number of metastases allowed in 
a clinical protocol and the actual number of metastases 
of enrolled patients: for example, the SABR-COMET 
randomised phase II trial on OMD allowed patients with up 
to 5 metastases but only 7 of the 99 patients included in the 
study had more than three (9). Whether the number and 
the type of involved organ contribute to the definition of 
OMD is currently unknown.
Additionally, there are more factors beyond the number 
of metastases that potentially define OMD, influence the 
prognosis and treatment strategy: 
	Did oligometastases occur at the time of primary 
diagnosis (synchronous) or at later during treatment/
follow-ups (metachronous) (10)?
	Do metastatic lymph nodes, in case of NSCLC 
mediastinal lymph nodes in particular, count towards 
the total number of metastases (11)? 
	How should differences regarding the primary 
tumor (size, invasion of adjacent structures, response 
to therapy) be considered?
	Was the  pat ient  d iagnos i s  and t reated  for 
polymetastatic or OMD before the current diagnosis 
of OMD?
In addition, other criteria such as the exclusion of 
untreated intracranial disease (7) renders many studies on 
oligometastasis difficult to compare. In the Gomez study, an 
additional criterion is the response to systemic therapy, which 
is certainly a factor contributing to the exceptional OS. 
Selection of the optimal local treatment 
approach
Studies as the one by Gomez et al. contribute to the 
paradigm shift towards the importance of local therapy not 
only for palliation but also to improve survival of patients 
with OMD. The question of the optimal local treatment 
modality and its integration into a multimodality treatment 
Table 1 Important studies on OMD in NSCLC
Study Design Enrolment Treatment concept Main inclusion criteria Outcome
De Ruysscher  
et al., 2012 (6)
Multicenter, single 
arm phase II trial
40 patients SoC-ST + SBRT/
surgery
Four metastases or less Median OS: 13.5 months
Iyengar et al., 
2017 (7)
Single-institution, 
randomized phase II 
trial
29 patients SoC-ST vs. SBRT + 
SoC-ST
Five extracranial 
metastases or less
Median PFS: 3.5 months (SoC-ST)  
vs. 9.7 months (SBRT + SoC-ST)
Gomez et al., 
2019 (5)
Multicenter, 
randomized phase II 
trial 
49 patients SoC-ST vs. SoC-ST  
& SBRT/surgery
Three metastases or less,  
at least stable after 3 
months of SoC-ST
Median PFS: 4.4 months (SoC-ST) 
vs. 14.2 (SBRT/surgery + SoC-ST); 
median OS: 17.0 months vs. 41.2
SoC, standard of care; PFS, progression-free survival; OS, overall survival; ST, systemic therapy; OMD, oligometastatic disease; NSCLC, 
non-small cell lung cancer.
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concept is therefore highly relevant. The Gomez et al.’s 
study allowed surgery and radiotherapy or a combination 
of both: after interdisciplinary discussion, the largest 
group (48%) of patients was treated with stereotactic body 
radiation therapy (SBRT) for all lesions and 24% received a 
combination of surgery and radiotherapy. This supports the 
importance of SBRT in the oligometastatic setting where 
the ability to perform the treatment without hospitalisation 
and tightly integrated into a systemic therapy backbone 
is highly relevant. However, the pros and cons of all local 
treatment modalities should be considered on a patient 
and lesion individual basis: what is the expected toxicity, 
probability of complete ablation/removal, influence on 
short and long-term quality of life, associated costs and 
potential interactions with systemic therapy.
Despite stereotactic radiotherapy being the less invasive 
procedure and considered a rather safe treatment modality, 
complications have been described. In addition to the 
aforementioned toxicities of the Gomez et al.’s study, 
the SABR-COMET trial noted three treatment-related 
grade 5 toxicities (one death from radiation pneumonitis, 
pulmonary abscess and subdural haemorrhage respectively) 
in the SABR group compared to none in the control group.
Prospective data on a combination of radiotherapy 
and novel targeted therapies is lacking. However, 
retrospective data suggests the safety of its application 
with few combinations where an increased risk has been 
observed. A potentially increased risk of severe toxicity was 
noted especially when combining extra-cranial SRT with 
bevacizumab and sorafenib and cranial SRT with BRAF 
inhibitors (12).
Whether radiotherapy is delivered concurrently to 
systemic therapy or whether systemic therapy is paused 
for a short period of time is another open question. Again, 
prospective data is missing, but considering the long 
biochemical and even longer biological half-life of many 
modern drugs and considering the possible risk of disease 
flare when the systemic therapy is paused, concurrent 
treatment appears as the most reasonable strategy (13).
Integration of immune checkpoint inhibition into 
treatment of OMD
The dominant pattern of disease recurrence after combined 
modality treatment for OMD is distant with 75–80% 
of all patients failing. This calls for the integration of 
more effective systemic therapy into the OMD treatment 
algorithms. Immune checkpoint inhibition appears to be 
particularly promising, as this has become the standard of 
care in first line treatment of polymetastatic NSCLC: either 
single-agent immune checkpoint inhibition for patients 
with PD-L1 status of ≥50% or combined chemotherapy 
and immune checkpoint inhibition (14). 
Preclinical data suggest that radiotherapy might be 
a synergistic partner for the combination with immune 
checkpoint inhibition (15): radiotherapy can increase 
leukocyte adhesion to the vascular endothelium (16), 
upregulate programmed death-ligand 1 (PD-L1) expression 
on tumor cells (17), cause the release of various inflammatory 
mediators (18) and affect the tumor microenvironment (19).
The available clinical data support these synergistic 
effects of radiotherapy and immunotherapy. The PACIFIC 
study, a randomized phase III trial in unresectable stage 
III NSCLC, compared consolidation therapy with anti-
PD-L1 antibody Durvalumab following definitive 
radiochemotherapy to placebo (20). For the first time in 
decades, a significant and clinically relevant improvement 
of OS was achieved: 24-month OS rate was 66.3% in the 
durvalumab group, as compared with 55.6% in the control 
group. And this came without added severe toxicity. A 
secondary analysis suggested the largest benefit in patients, 
where Durvalumab was initiated within 14 days after 
completion of radiotherapy, indicating an interaction 
between these treatment modalities. 
The safety and efficacy of combining immunotherapy 
and SBRT is also supported by the PEMBRO-RT study. 
This randomized phase II trial, compared Pembrolizumab 
alone to Pembrolizumab preceded by SBRT in 3 fractions 
of 8 Gy to a single metastatic tumor site. The study noted 
good tolerance of the SBRT/Pembrolizumab combination 
and an increase in the overall response rate at 12 weeks 
from 18% in the control arm to 36% in the experimental 
arm although the predefined criteria for meaningful clinical 
benefit were not met (21). Especially the PD-L1-negative 
subgroup showed significant improvement in PFS and OS. 
Despite these positive signals, different highly relevant 
questions need to be addressed: 
	What is the optimal timing and sequencing of 
SBRT and immunotherapy? While performing local 
therapy first, as it is routinely done in the situation of 
locally advanced disease, might create an advantage 
by drastically reducing tumor burden in a short 
period of time, beginning with systemic therapy 
could help identifying patients who progress rapidly 
and therefore will not benefit from local therapy;
	Is there an optimal dose or fractionation scheme 
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of radiotherapy? The evidence as to which dose or 
scheme creates the strongest abscopal effect, i.e., 
inducing a systemic effect by irradiating a single 
tumor site in combination with immunotherapy, is 
conflicting (22);
	How many lesions should be treated locally? While 
studies have been initiated trying to create an 
abscopal effect, others have called to abandon single-
site irradiation in favor of treating more, if not all 
tumor manifestations for optimal results (23);
	Furthermore, additional research is needed on the 
optimal therapy once a limited number of lesions 
progress while the patient is still undergoing 
systemic therapy (oligoprogression). Do patients 
benefit from adding SBRT to the progressive lesions 
compared to continuing with systemic therapy alone 
or should the systemic therapy be changed? One study 
intending to provide answers to this question for TKI 
therapy is the HALT trial, a phase II/III multicenter 
RCT evaluating the addition of SBRT to three or 
fewer sites of oligoprogressive disease (24).
The ETOP CHESS (NCT03965468) trial will address 
several of the questions above and test the optimal 
integration of immunotherapy, chemotherapy, radiotherapy 
and surgery for synchronous oligometastatic NSCLC: 
durvalumab, chemotherapy and SBRT to all oligometastatic 
sites will be combined to maximize local and especially 
systemic efficacy in an induction phase; this will be followed 
by radical treatment of the primary, surgery of radiotherapy 
in unresectable patients. Translational studies will hopefully 
also shed more light into the biology of OMD. 
In conclusion, the updated study by Gomez et al. 
provides important evidence for the concept of OMD in 
NSCLC and underlines the necessity to initiate new studies 
investigating treatment concepts for oligometastatic cancer 
in the age of immunotherapy. 
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